Comment from Ajenat Pharmaceuticals LLC
AnonymousSupportBusiness
Summary: Ajenat Pharmaceuticals LLC is requesting that the FDA add Enclomiphene Citrate to the 503B Bulk Drug Substances List. They argue that the substance is a well-established therapeutic agent for hypogonadism and that its inclusion will improve patient access to high-quality, standardized compounded medications.
Ajenat Pharmaceuticals LLC submits this comment in support of adding Enclomiphene Citrate (UNII: J303A6U9Y6) to the 503B Bulk Drug Substances List under Docket No. FDA-2015-N-3469.
Enclomiphene Citrate is a well-established therapeutic agent with significant clinical utility, particularly in the management of hypogonadism. Given the increasing demand for these agents in patient care, particularly in specialized and compounded formulations, their availability under 503B outsourcing facilities would enhance patient access and ensure quality-controlled production standards.
We believe that including these substances on the 503B bulk drug substances list aligns with the FDA's mission to promote patient safety while maintaining regulatory oversight of high-quality compounded medications. Ajenat Pharmaceuticals strongly urges the FDA to approve these nominations to expand patient treatment options and support healthcare providers in addressing unmet medical needs.
We appreciate the FDA’s consideration of this recommendation and look forward to continued engagement on this matter.